Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Autonomous & Electric Vehicles (DRIV) vs Cassava Sciences Inc (FLNA) Price & Performance

Global X Autonomous & Electric VehiclesTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Global X Autonomous & Electric Vehicles vs Cassava Sciences Inc — how do they compare? Global X Autonomous & Electric Vehicles trades at $35.42, while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Global X Autonomous & Electric Vehicles is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

DRIVFLNA
Sector
Sector/ThematicHealth
52-Week High
$42.53$4.64
52-Week Low
$25.23$0.87
Market Cap
$47.75M
Enterprise Value
-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Autonomous & Electric Vehicles

DRIV trades at $35.78, up 2.55% today, with a bullish technical signal driven by moving averages. The stock shows strong year-to-date performance, supported by positive sentiment in the electric vehicle sector. Key support is at $35, with resistance at $36. Recent news highlights global EV sales growth and China's expanding market ambitions.

Outlook remains positive due to sector tailwinds and autonomous driving advancements, but risks include regulatory pressures and competitive threats from Chinese automakers. Institutional interest is strong, though overbought RSI signals caution near-term.

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

Returns comparison

Trailing returns across standard periods

About Global X Autonomous & Electric Vehicles

DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.

Read more on DRIV

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA